Treace to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 02 2025 - 3:15PM
Treace Medical Concepts, Inc. (“Treace” or the “Company”)
(NasdaqGS: TMCI), a medical technology company driving a
fundamental shift in the surgical treatment of bunions and related
midfoot deformities through its
flagship Lapiplasty® and Adductoplasty® Procedures,
today announced that John T. Treace, Chief Executive Officer, will
present at the 43rd Annual J.P. Morgan Healthcare Conference on
Tuesday, January 14, 2025, beginning at approximately 9:00 am PT.
A live webcast and replay of the fireside chat
will be available on the Company’s investors relations website at
https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be important to
investors in the “Investor Relations” section of its website at
www.treace.com. The Company encourages investors and potential
investors to consult the Treace website regularly for important
information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical
technology company with the goal of advancing the standard of care
for the surgical management of bunion and related midfoot
deformities. Bunions are complex 3-dimensional deformities that
originate from an unstable joint in the middle of the foot and
affect approximately 67 million Americans, of which Treace
estimates 1.1 million are annual surgical candidates. Treace has
pioneered and patented the Lapiplasty® 3D Bunion Correction® System
– a combination of instruments, implants, and surgical methods
designed to surgically correct all three planes of the bunion
deformity and secure the unstable joint, addressing the root cause
of the bunion and helping patients get back to their active
lifestyles. To further support the needs of bunion patients, Treace
has introduced its Adductoplasty® Midfoot Correction System,
designed for reproducible surgical correction of midfoot
deformities. The Company continues to expand its footprint in the
foot and ankle market with the introduction of its SpeedPlate™
Rapid Compression Implants, an innovative fixation platform with
broad versatility across Lapiplasty® and Adductoplasty® procedures,
as well as other common bone fusion
To learn more about Treace, connect with us
on LinkedIn, X, Facebook and Instagram.
Contacts:Treace Medical
ConceptsMark L. HairChief Financial
Officermhair@treace.net(904) 373-5940
Investors:Gilmartin
GroupVivian Cervantes IR@treace.net
Treace Medical Concepts (NASDAQ:TMCI)
Historical Stock Chart
From Dec 2024 to Jan 2025
Treace Medical Concepts (NASDAQ:TMCI)
Historical Stock Chart
From Jan 2024 to Jan 2025